Menu Search
Equities

Biogen Inc

BIIB:NSQ

Biogen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)157.90
  • Today's Change-0.11 / -0.07%
  • Shares traded1.70m
  • 1 Year change-31.72%
  • Beta-0.0808
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Biogen Inc's revenues fell -3.32% from 10.17bn to 9.84bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 3.05bn to 1.16bn, a -61.89% decrease.
Gross margin75.59%
Net profit margin16.80%
Operating margin22.56%
Return on assets5.71%
Return on equity10.47%
Return on investment7.01%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Biogen Inc fell by 2.37bn. However, the company earned 1.55bn from its operations for a Cash Flow Margin of 15.73%. In addition the company generated 149.30m cash from financing while 4.10bn was spent on investing.
Cash flow per share15.51
Price/Cash flow per share10.16
Book value per share112.90
Tangible book value per share0.4665
More ▼

Balance sheet in USDView more

Biogen Inc has a Debt to Total Capital ratio of 27.78%, a lower figure than the previous year's 46.86%.
Current ratio1.26
Quick ratio0.8039
Total debt/total equity0.3847
Total debt/total capital0.2778
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -61.79%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-18.14
EPS (TTM) vs
TTM 1 year ago		10.09
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.